cephalosporin c has been researched along with Infections, Serratia in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dortet, L; Jeannot, K; Naas, T; Nordmann, P; Oueslati, S; Tandé, D | 1 |
| Abdile, AA; Doi, Y; Harris, PN; Huh, K; Huxley, RR; O'Neal, CS; Pandeya, N; Paterson, DL; Paynter, S; Shen, AW; Talbot, TR; Wei, JY | 1 |
| Ghebremedhin, B; Rasche, K; Yayan, J | 1 |
| Heeney, MM; Hettmer, S | 1 |
| Doumith, M; Ellington, MJ; Hornsey, M; Hudson, S; Livermore, DM; Woodford, N | 1 |
| Chang, HJ; Hsu, PC; Huang, CT; Lee, MH; Wu, YM; Yang, CC; Ye, JJ | 1 |
| Aspöck, C; Assadian, O; Berger, A; Hirschl, AM; Kohlhauser, C; Mustafa, S | 1 |
| Choi, SH; Choo, EJ; Chung, JW; Kim, BN; Kim, MN; Kim, NJ; Kim, TH; Kim, YS; Ryu, J; Woo, JH | 1 |
| Bemer, P; Drugeon, H; Mammeri, H; Nordmann, P; Poirel, L | 1 |
| Cheng, KC; Chuang, YC; Huang, GC; Wu, LT; Yu, WL | 1 |
| Bagattini, M; Crivaro, V; Raimondi, F; Rossano, F; Salza, MF; Triassi, M; Zarrilli, R | 1 |
| Gianneli, D; Mentis, AF; Nikolopoulou, C; Tzelepi, E; Tzouvelekis, LS | 1 |
| Domínguez Herrera, JM; Hernández Guisado, JM; Infante Cossio, P; Jiménez Mejías, ME | 1 |
| Arends, JP; Brus, F; de Vries-Hospers, HG; Kimpen, JL | 1 |
| Beauchamp, D; Bergeron, MG; Morin, NJ; Simard, M; Turcotte, A | 1 |
| Pechère, JC; Vladoianu, IR | 1 |
| Horiba, M; Nagata, Y; Naide, Y; Suzuki, K | 1 |
1 review(s) available for cephalosporin c and Infections, Serratia
| Article | Year |
|---|---|
Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Enterobacteriaceae Infections; Humans; Quinolones; Serratia Infections; Survival Analysis; Treatment Outcome | 2016 |
16 other study(ies) available for cephalosporin c and Infections, Serratia
| Article | Year |
|---|---|
Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity.
Topics: Adult; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Cephalosporins; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA; Serratia Infections; Serratia marcescens | 2015 |
Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study.
Topics: Aged; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cefepime; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Germany; Hospital Mortality; Hospitals, University; Humans; Kaplan-Meier Estimate; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Proteus Infections; Proteus mirabilis; Retrospective Studies; Serratia Infections; Serratia marcescens | 2016 |
Cefepime-induced neutropenia in a teenager.
Topics: Accidents, Traffic; Adolescent; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Humans; Neutropenia; Serratia Infections; Serratia marcescens; Spinal Fractures; Spinal Fusion; Surgical Wound Infection; Vancomycin | 2008 |
Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biological Transport, Active; Cefpirome; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Gene Deletion; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Minocycline; Mutation; Reverse Transcriptase Polymerase Chain Reaction; Selection, Genetic; Serratia Infections; Serratia marcescens; Tigecycline; Up-Regulation | 2010 |
Serratia marcescens meningitis: epidemiology, prognostic factors and treatment outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Meningitis, Bacterial; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Serratia Infections; Serratia marcescens; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Nosocomial outbreak of Serratia marcescens in a neonatal intensive care unit.
Topics: Antibiotic Prophylaxis; Austria; Cefuroxime; Cephalosporins; Cross Infection; Disease Outbreaks; Female; Humans; Infant, Newborn; Infection Control; Intensive Care Units, Neonatal; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Risk Factors; Serratia Infections; Serratia marcescens | 2002 |
Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteremia; Cephalosporins; Child; Child, Preschool; Cross Infection; Drug Resistance, Bacterial; Female; Hospitals, University; Humans; Incidence; Infant; Infant, Newborn; Korea; Length of Stay; Male; Middle Aged; Morbidity; Recurrence; Retrospective Studies; Risk Factors; Serratia Infections; Survival Rate | 2002 |
Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate.
Topics: Amino Acid Sequence; Bacterial Proteins; beta-Lactamases; Cefepime; Cefpirome; Cephalosporin Resistance; Cephalosporinase; Cephalosporins; Chromosomes, Bacterial; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Plasmids; Sequence Deletion; Serratia Infections; Serratia marcescens | 2004 |
Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan.
Topics: Amikacin; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Taiwan | 2006 |
Risk factors for extended-spectrum beta-lactamase-producing Serratia marcescens and Klebsiella pneumoniae acquisition in a neonatal intensive care unit.
Topics: Acetyltransferases; Ampicillin; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Birth Weight; Carrier State; Cephalosporins; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genotype; Gentamicins; Gestational Age; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Italy; Klebsiella Infections; Klebsiella pneumoniae; Molecular Epidemiology; Molecular Sequence Data; Plasmids; Risk Factors; Sequence Analysis, DNA; Serratia Infections; Serratia marcescens; Surgical Procedures, Operative | 2007 |
Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals.
Topics: beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Cross Infection; DNA, Bacterial; Greece; Humans; Microbial Sensitivity Tests; Plasmids; Serratia Infections; Serratia marcescens | 1994 |
[Acute bacterial parotitis caused by Serratia marcescens].
Topics: Acute Disease; Aztreonam; Cefotaxime; Cephalosporins; Child; Diagnosis, Differential; Female; Humans; Middle Aged; Monobactams; Parotitis; Serratia Infections; Serratia marcescens; Time Factors; Tomography, X-Ray Computed | 1996 |
Successful medical treatment of multiple Serratia marcescens brain abscesses in a neonate.
Topics: Aminoglycosides; Brain Abscess; Cephalosporins; Drug Therapy, Combination; Humans; Infant, Newborn; Male; Serratia Infections; Serratia marcescens | 1996 |
Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.
Topics: Animals; Aztreonam; Ceftazidime; Cephalosporins; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Fibrin; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Serratia Infections; Serratia marcescens | 1997 |
Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.
Topics: Animals; Cefepime; Ceftazidime; Cephalosporins; Citrobacter freundii; Disease Models, Animal; Drug Resistance, Microbial; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia Infections; Serratia marcescens; Virulence | 1992 |
[Clinical response of chemotherapeutic agents with different activities on chronic complicated pyelonephritis with renal stone. A proposed index of local antimicrobial activity].
Topics: Anti-Bacterial Agents; Cephalosporins; Chronic Disease; Humans; Kidney; Kidney Calculi; Male; Middle Aged; Pyelonephritis; Remission Induction; Serratia Infections; Serratia marcescens | 1991 |